Clinical Trial Update: Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis [Phase 2]

View source ↗

Summary

Clinical trial update indicating completion of a Phase 2 study evaluating ustekinumab for relapse of refractory giant cell arteritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Patients Relapsing Refractory Giant Cell Arteritis | Phase 2 | Status: COMPLETED